Sökning: onr:"swepub:oai:gup.ub.gu.se/219567" > MRI assessment of e...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04622naa a2200637 4500 | |
001 | oai:gup.ub.gu.se/219567 | |
003 | SwePub | |
008 | 240910s2015 | |||||||||||000 ||eng| | |
024 | 7 | a https://gup.ub.gu.se/publication/2195672 URI |
024 | 7 | a https://doi.org/10.1136/annrheumdis-2014-2063592 DOI |
040 | a (SwePub)gu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Ostergaard, M.4 aut |
245 | 1 0 | a MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16 |
264 | c 2014-12-15 | |
264 | 1 | b BMJ,c 2015 |
520 | a Objectives To identify the first time point of an MRI-verified response to certolizumab pegol (CZP) therapy in patients with rheumatoid arthritis (RA). Methods Forty-one patients with active RA despite disease-modifying antirheumatic drug therapy were randomised 2:1 to CZP (CZP loading dose 400mg every 2weeksat weeks 0-4; CZP 200mg every 2weeksat weeks 6-16) or placeboCZP (placebo at weeks 0-2; CZP loading dose at weeks 2-6; CZP 200mg every 2weeks at weeks 8-16). Contrast-enhanced MRI of one hand and wrist was acquired at baseline (week 0) and weeks 1, 2, 4, 8 and 16. All six time points were read simultaneously, blinded to time, using the Outcome Measures in Rheumatology Clinical Trials RA MRI scoring system. Primary outcome was change in synovitis score in the CZP group; secondary outcomes were change in bone oedema (osteitis) and erosion scores and clinical outcome measures. Results Forty patients were treated (27 CZP, 13 placeboCZP), and 36 (24 CZP, 12 placeboCZP) completed week 16. In the CZP group, there were significant reductions from baseline synovitis (Hodges-Lehmann estimate of median change, -1.5, p=0.049) and osteitis scores (-2.5, p=0.031) at week 16. Numerical, but statistically insignificant, MRI inflammation reductions were observed at weeks 1-2 in the CZP group. No significant change was seen in bone erosion score. Improvements across all clinical outcomes were seen in the CZP group. Conclusions CZP reduced MRI synovitis and osteitis scores at week 16, despite small sample size and the technical challenge of reading six time points simultaneously. This study provides essential information on optimal MRI timing for subsequent trials. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reumatologi och inflammation0 (SwePub)302102 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Rheumatology and Autoimmunity0 (SwePub)302102 hsv//eng |
653 | a Rheumatoid Arthritis | |
653 | a Magnetic Resonance Imaging | |
653 | a Anti-TNF | |
653 | a Inflammation | |
653 | a Synovitis | |
653 | a BONE-MARROW EDEMA | |
653 | a SUBSEQUENT RADIOGRAPHIC PROGRESSION | |
653 | a SPACE NARROWING | |
653 | a SCORE | |
653 | a DISEASE-ACTIVITY | |
653 | a INFLAMMATORY ACTIVITY | |
653 | a STRUCTURAL DAMAGE | |
653 | a RELIABILITY | |
653 | a SYNOVITIS | |
653 | a RESPONSIVENESS | |
653 | a METHOTREXATE | |
653 | a Rheumatology | |
700 | 1 | a Jacobsson, Lennart T. H.,d 1954u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research4 aut0 (Swepub:gu)xjacle |
700 | 1 | a Schaufelberger, C.u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research4 aut |
700 | 1 | a Hansen, M. S.4 aut |
700 | 1 | a Bijlsma, J. W. J.4 aut |
700 | 1 | a Dudek, A.4 aut |
700 | 1 | a Rell-Bakalarska, M.4 aut |
700 | 1 | a Staelens, F.4 aut |
700 | 1 | a Haake, R.4 aut |
700 | 1 | a Sundman-Engberg, B.4 aut |
700 | 1 | a Bliddal, H.4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning4 org |
773 | 0 | t Annals of the Rheumatic Diseasesd : BMJg 74:6, s. 1156-1163q 74:6<1156-1163x 0003-4967x 1468-2060 |
856 | 4 | u https://ard.bmj.com/content/74/6/1156.full.pdf |
856 | 4 8 | u https://gup.ub.gu.se/publication/219567 |
856 | 4 8 | u https://doi.org/10.1136/annrheumdis-2014-206359 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy